These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 19341846)
1. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive. Kaunitz AM; Portman DJ; Hait H; Reape KZ Contraception; 2009 May; 79(5):350-5. PubMed ID: 19341846 [TBL] [Abstract][Full Text] [Related]
2. A look at the long-term safety of an extended-regimen OC. Davis MG; Reape KZ; Hait H J Fam Pract; 2010 May; 59(5):E3. PubMed ID: 20544040 [TBL] [Abstract][Full Text] [Related]
3. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Teichmann A; Apter D; Emerich J; Greven K; Klasa-Mazurkiewicz D; Melis GB; Spaczynski M; Grubb GS; Constantine GD; Spielmann D Contraception; 2009 Dec; 80(6):504-11. PubMed ID: 19913143 [TBL] [Abstract][Full Text] [Related]
4. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Sulak P; Willis S; Kuehl T; Coffee A; Clark J Headache; 2007 Jan; 47(1):27-37. PubMed ID: 17355491 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Anderson FD; Gibbons W; Portman D Contraception; 2006 Mar; 73(3):229-34. PubMed ID: 16472561 [TBL] [Abstract][Full Text] [Related]
6. A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens. Darwish M; Bond M; Ricciotti N; Hsieh J; Fiedler-Kelly J; Grasela T Reprod Sci; 2014 Nov; 21(11):1401-10. PubMed ID: 24647707 [TBL] [Abstract][Full Text] [Related]
7. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Lange E; Mellinger U; Palombo-Kinne E; Kuhl H Contraception; 2011 Aug; 84(2):133-43. PubMed ID: 21757054 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive. Portman DJ; Kaunitz AM; Howard B; Weiss H; Hsieh J; Ricciotti N Contraception; 2014 Apr; 89(4):299-306. PubMed ID: 24576794 [TBL] [Abstract][Full Text] [Related]
9. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Sulak PJ; Kuehl TJ; Coffee A; Willis S Am J Obstet Gynecol; 2006 Oct; 195(4):935-41. PubMed ID: 16647684 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo. Poindexter A; Reape KZ; Hait H Contraception; 2008 Aug; 78(2):113-9. PubMed ID: 18672111 [TBL] [Abstract][Full Text] [Related]
11. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Coffee AL; Sulak PJ; Kuehl TJ Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150 [TBL] [Abstract][Full Text] [Related]
12. A comparison between monophasic levonorgestrel-ethinyl estradiol 150/30 and triphasic levonorgestrel-ethinyl estradiol 50-75-125/30-40-30 contraceptive pills for side effects and patient satisfaction: a study in Iran. Kashanian M; Shahpourian F; Zare O Eur J Obstet Gynecol Reprod Biol; 2010 May; 150(1):47-51. PubMed ID: 20185226 [TBL] [Abstract][Full Text] [Related]
13. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given? Edelman AB; Koontz SL; Nichols MD; Jensen JT Obstet Gynecol; 2006 Mar; 107(3):657-65. PubMed ID: 16507938 [TBL] [Abstract][Full Text] [Related]
14. Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo. Anderson FD; Feldman R; Reape KZ Contraception; 2008 Feb; 77(2):91-6. PubMed ID: 18226671 [TBL] [Abstract][Full Text] [Related]
15. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Stewart FH; Kaunitz AM; Laguardia KD; Karvois DL; Fisher AC; Friedman AJ Obstet Gynecol; 2005 Jun; 105(6):1389-96. PubMed ID: 15932834 [TBL] [Abstract][Full Text] [Related]
16. Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study. Merz M; Kroll R; Lynen R; Bangerter K Contraception; 2015 Feb; 91(2):113-20. PubMed ID: 25453585 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Archer DF; Jensen JT; Johnson JV; Borisute H; Grubb GS; Constantine GD Contraception; 2006 Dec; 74(6):439-45. PubMed ID: 17157099 [TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Coffee AL; Kuehl TJ; Willis S; Sulak PJ Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986 [TBL] [Abstract][Full Text] [Related]
19. Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive. Westhoff CL; Hait HI; Reape KZ Contraception; 2012 Mar; 85(3):235-9. PubMed ID: 22067763 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]